Clene Inc.
About Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $200.0K
- Net income
- -$26.2M
- Total assets
- $18.1M
- Market cap
- $69.6M
- Gross margin
- 79.5%
- Operating margin
- -9676.3%
- Net margin
- -11520.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $342.0K
- Cost of revenue
- $70.0K
- Gross profit
- $272.0K
- Operating expenses
- $33.4M
- Operating income
- -$33.1M
- Income tax
- $0
- Net income
- -$39.4M
- EPS (basic)
- $-5.67
Balance sheet
- Total assets
- $27.3M
- Current assets
- $16.2M
- Total liabilities
- $36.2M
- Current liabilities
- $10.3M
- Shareholders’ equity
- -$8.9M
Cash flow
- Operating cash flow
- -$21.3M
- Investing cash flow
- $6.3M
- Financing cash flow
- -$1.5M
- Net cash flow
- -$16.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $69.6M
- Shares outstanding
- 13.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 31, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.2M in FY2025.
- Revenue grew 66% from FY2020 to FY2024.
- Gross margin of 79.5%, net margin -11520.5%.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Clene Inc..
Write a review
News about Clene Inc.
News & sentiment via Polygon.io
